GPC1 specific CAR-T cells eradicate established solid tumor without adverse effects and synergize with anti-PD-1 Ab

Current xenogeneic mouse models cannot evaluate on-target off-tumor adverse effect, hindering the development of chimeric antigen receptor (CAR) T cell therapies for solid tumors, due to limited human/mouse cross-reactivity of antibodies used in CAR and sever graft-versus-host disease induced by adm...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:eLife
Autors principals: Kato, Daiki, Yaguchi, Tomonori, Iwata, Takashi, Katoh, Yuki, Morii, Kenji, Tsubota, Kinya, Takise, Yoshiaki, Tamiya, Masaki, Kamada, Haruhiko, Akiba, Hiroki, Tsumoto, Kouhei, Serada, Satoshi, Naka, Tetsuji, Nishimura, Ryohei, Nakagawa, Takayuki, Kawakami, Yutaka
Format: Artigo
Idioma:Inglês
Publicat: eLife Sciences Publications, Ltd 2020
Matèries:
Cancer Biology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7108862/
https://ncbi.nlm.nih.gov/pubmed/32228854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7554/eLife.49392
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars